

PRIOR AUTHORIZATION CRITERIA

BRAND NAME
(generic)

DARAPRIM
(pyrimethamine)

Status: CVS Caremark Criteria
Type: Initial Prior Authorization

POLICY

FDA-APPROVED INDICATIONS

Treatment of Toxoplasmosis

Daraprim is indicated for the treatment of toxoplasmosis when used conjointly with a sulfonamide, since synergism exists with this combination.

Compendial Uses

Toxoplasmosis; Prophylaxis^{2,3,4,5}

Pneumocystis jiroveci pneumonia; Prophylaxis^{2,3,4}

Cystoisosporiasis^{2,4,5}

COVERAGE CRITERIA

The requested drug will be covered with prior authorization when the following criteria are met:

- The requested drug is being prescribed for the treatment of congenital toxoplasmosis in a pediatric patient
OR
- The requested drug is being prescribed for the treatment of toxoplasmosis
OR
- The patient has an intolerance or contraindication to sulfamethoxazole/trimethoprim AND the requested drug is being prescribed for any of the following: A) Toxoplasmosis prophylaxis, B) Pneumocystis jiroveci pneumonia prophylaxis
AND
 - The patient has not had a CD4 cell count of greater than 200/mm³ for at least 3 months
- OR**
- The patient has an intolerance or contraindication to sulfamethoxazole/trimethoprim AND the requested drug is being prescribed for Cystoisosporiasis
AND
 - The patient has not had a CD4 cell count of greater than 200/mm³ for at least 6 months

REFERENCES

1. Daraprim [package insert]. New York, NY: Vyera Pharmaceuticals, LLC; August 2017.
2. Lexicomp Online, AHFS DI (Adult and Pediatric) Online. Hudson, OH: Wolters Kluwer Clinical Drug Information, Inc. <http://online.lexi.com/>. Accessed December 2019.
3. Micromedex (electronic version). Truven Health Analytics, Greenwood Village, Colorado, USA. <http://www.micromedexsolutions.com/>. Accessed December 2019.
4. Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. Available at http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf. Accessed December 2019.
5. Panel on Opportunistic Infections in HIV-Exposed and HIV-Infected Children. Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Exposed and HIV-Infected Children. Department of Health and Human

Services. Recommendations from the National Institutes of Health, Centers for Disease Control and Prevention, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics. Available at http://aidsinfo.nih.gov/contentfiles/lvguidelines/oi_guidelines_pediatrics.pdf. Accessed December 2019.

6. Guidelines for the Treatment of Malaria in the United States. Centers for Disease Control and Prevention. Available at https://www.cdc.gov/malaria/resources/pdf/Malaria_Treatment_Table_120419.pdf. Accessed December 2019.
7. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV. Department of Health and Human Services. Available at <http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf>. Accessed May 2020.